{"id":6171,"date":"2026-10-16T08:32:51","date_gmt":"2026-10-16T03:02:51","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-16\/"},"modified":"2026-10-16T08:32:54","modified_gmt":"2026-10-16T03:02:54","slug":"mankind-share-price-today-2026-10-16","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-16\/","title":{"rendered":"Mankind Pharma in Focus After Acquiring Majority Stake in Armed Cell Therapeutics | 16 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"premarket\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: MANKIND<\/strong> \u00b7 16 October 2026 \u00b7 Pre-market update<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Previous close<\/div>\n<div>\u20b92,347.60<\/div>\n<\/div>\n<div>\n<div>Previous day change<\/div>\n<div>+0.54%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,365.00 \/ \u20b92,321.10<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>6.45 lakh<\/div>\n<\/div>\n<div>\n<div>Previous trading day<\/div>\n<div>15 October 2026<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Mankind Pharma Limited is in focus ahead of the market open following its board&#x27;s approval to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. via its subsidiary. The strategic move marks the company&#x27;s entry into next-generation CAR-T therapies for cancer. Additionally, the company received an ESG rating of 71 from NSE Sustainability Ratings and Analytics Limited.<\/li>\n<li>Mankind Pharma&#x27;s board approved an additional investment of up to EUR 45 million in its wholly-owned subsidiary, Mankind Netherlands B.V., taking the aggregate investment limit to EUR 50 million. This capital will be utilized to invest EUR 48 million in installments to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a biotechnology company developing next-generation CAR-T cell therapies for cancer with lead programs in non-Hodgkin lymphoma and small cell lung cancer.<\/li>\n<li>Trading volume was 1.07 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Mankind Pharma Company News Before Market Open<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Mankind Pharma Limited is in focus ahead of the market open following its board&#x27;s approval to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. via its subsidiary. The strategic move marks the company&#x27;s entry into next-generation CAR-T therapies for cancer. Additionally, the company received an ESG rating of 71 from NSE Sustainability Ratings and Analytics Limited.<\/p>\n<p class=\"wt-copy\">The acquisition of a majority stake in Armed Cell Therapeutics broadens Mankind Pharma&#x27;s technological footprint into advanced global oncology research. The planned EUR 48 million investment underlines the company&#x27;s capital allocation towards specialized therapeutic segments outside its core domestic formulations. Technical baseline: The stock closed the previous trading day on October 15, 2026, at \u20b92,347.60, up 0.54%, trading within a prior day range of \u20b92,321.10 to \u20b92,365.00.<\/p>\n<p class=\"wt-copy\">6.45 lakh shares traded on 15 October 2026. This compares with a 20-day average daily volume of 6.03 lakh shares (1.07 times). The five-day average daily volume was 4.25 lakh shares.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Company-specific context<\/div>\n<div class=\"wt-card-body\"><strong>Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics<\/strong><\/p>\n<p class=\"wt-copy\">The acquisition of a majority stake in Armed Cell Therapeutics broadens Mankind Pharma&#x27;s technological footprint into advanced global oncology research. The planned EUR 48 million investment underlines the company&#x27;s capital allocation towards specialized therapeutic segments outside its core domestic formulations. Technical baseline: The stock closed the previous trading day on October 15, 2026, at \u20b92,347.60, up 0.54%, trading within a prior day range of \u20b92,321.10 to \u20b92,365.00.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Mankind Pharma to Acquire 70% Stake in Armed Cell Therapeutics<\/div>\n<div class=\"wt-card-date\">15 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mankind Pharma&#x27;s board approved an additional investment of up to EUR 45 million in its wholly-owned subsidiary, Mankind Netherlands B.V., taking the aggregate investment limit to EUR 50 million. This capital will be utilized to invest EUR 48 million in installments to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a biotechnology company developing next-generation CAR-T cell therapies for cancer with lead programs in non-Hodgkin lymphoma and small cell lung cancer.<\/p>\n<p class=\"wt-copy\">This acquisition represents a strategic entry into cutting-edge oncology and next-generation CAR-T cell therapies, aligning with the company&#x27;s long-term goal of building a global innovation-led pharmaceutical business.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Assigned ESG Rating of 71 by NSE Sustainability<\/div>\n<div class=\"wt-card-date\">15 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">NSE Sustainability Ratings and Analytics Limited independently assigned an Environmental, Social, and Governance (ESG) rating of &#x27;71&#x27; to Mankind Pharma for FY26, based on publicly available information without prior engagement by the company.<\/p>\n<p class=\"wt-copy\">Provides investors with an independent benchmark of the company&#x27;s ESG practices and sustainability transparency.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">16 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 15, 2026, titled &quot;Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies &quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026193306_Outcomefinalsd.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">16 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Outcome of Board Meeting held on October 15, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026192506_Outcomefinalsd.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">72.63%<\/div>\n<div class=\"wt-note\">72.66% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">9.45%<\/div>\n<div class=\"wt-note\">10.24% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">24.84%<\/div>\n<div class=\"wt-note\">24.70% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1697698_21072026100612_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 10.87% on 30 June 2026. This compares with 10.36% on 31 March 2026, a change of +0.51 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 36 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">NIPPON LIFE INDIA TRUSTEE LTD-A\/C NIPPON INDIA NIF<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">85.47 lakh shares \u00b7 2.07%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI ARBITRAGE OPPORTUNITIES FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">64.27 lakh shares \u00b7 1.56%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1697698_21072026100612_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Market sentiment and opening price action following the announcement of the cross-border acquisition and ESG rating.<\/li>\n<li>Management commentary regarding the timelines for completing the definitive agreements and funding tranches for ACTx.<\/li>\n<li>Volume participation and relative performance compared to the broader pharmaceutical sector at the market open.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-14\/\">Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.47% | 14 October 2026 \u2014 14 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-05\/\">Why Mankind Pharma Shares Fell 2.21% Today: Sector Weakness &amp; Context | 5 October 2026 \u2014 5 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-01\/\">Why Mankind Pharma Shares Are Down 2.36% Today | 1 October 2026 \u2014 1 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/mankind\/\">More Mankind Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Mankind Pharma company news?<\/h3>\n<p class=\"wt-copy\">Mankind Pharma&#x27;s board approved an additional investment of up to EUR 45 million in its wholly-owned subsidiary, Mankind Netherlands B.V., taking the aggregate investment limit to EUR 50 million. This capital will be utilized to invest EUR 48 million in installments to acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a biotechnology company developing next-generation CAR-T cell therapies for cancer with lead programs in non-Hodgkin lymphoma and small cell lung cancer.<\/p>\n<h3>How strong was Mankind Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">6.45 lakh shares traded, 1.07 times the 20-day average daily volume. The price and volume data are dated 15 October 2026.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-16\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-16\/\"}, \"headline\": \"Mankind Pharma in Focus After Acquiring Majority Stake in Armed Cell Therapeutics | 16 October 2026\", \"description\": \"Mankind Pharma stock in focus pre-market after approving a 70% stake acquisition in Armed Cell Therapeutics for CAR-T cancer therapies and receiving an ESG.\", \"datePublished\": \"2026-10-16T08:32:37.163734+05:30\", \"dateModified\": \"2026-10-16T08:32:37.163734+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/mankind-company-news-2026-10-16.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"General Updates\",\"summary\":\"General Updates\",\"source\":\"NSE\",\"published\":\"15-Oct-2026 20:40:25\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026204014_ESGRatingIntimation.pdf\",\"disclosure_text\":\"October 15, 2026 BSE Limited P J Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Code: 543904 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Symbol: MANKIND Dear Sir\/ Madam, Subject: Intimation of Environmental, Social and Governance (ESG) Rating Ref.: Regulation 30 & 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cListing Regulations\u201d) Pursuant to Regulations 30 and 51 of the Listing Regulations, we wish to inform you that NSE Sustainability Ratings and Analytics Limited (\u201cNSE Sustainability\u201d), a SEBI registered ESG Rating Provider, has assigned the Environmental, Social, and Governance (ESG) Rating of \u201871\u2019 to the Company. The Company has not engaged NSE Sustainability for the said rating, same has been independently assigned by NSE Sustainability for FY26, based on publicly available information. The above disclosure is also being made available on the Company\u2019s website at www.mankindpharma.com. This is for your information and records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer\"},{\"title\":\"Press Release\",\"summary\":\"a press release dated October 15, 2026, titled \\\"Press Release titled  Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies \\\".\",\"source\":\"NSE\",\"published\":\"15-Oct-2026 19:33:16\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026193306_Outcomefinalsd.pdf\",\"disclosure_text\":\"October 15, 2026 BSE Limited P J Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Code: 543904 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Symbol: MANKIND Dear Sir\/ Madam, Sub.: Outcome of Board Meeting Ref.: Regulation 30 & 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cListing Regulations\u201d) The Board of Directors of Mankind Pharma Limited (\u201cCompany\u201d), at its meeting held today, i.e., October 15, 2026, has, inter alia, considered and approved: i. an additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V. (\u201cMankind Netherlands\u201d), a wholly owned subsidiary of the Company in Netherlands, in one or more tranches, thereby increasing the aggregate investment limit to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn; ii. the acquisition of a majority stake (i.e., 70%) in Armed Cell Therapeutics B.V. (\u201cACTx\u201d) through Mankind Netherlands. ACTx is a Belgium-incorporated biotechnology company engaged in the development of next-generation chimeric antigen receptor T-cell (\u201cCAR-T\u201d) therapies for cancer. ACTx has a pipeline of next-generation CAR-T assets, with its lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. The detailed disclosures as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO\/49\/14\/14(7)2025-CFD-POD2\/I\/3762\/2026 dated January 30, 2026 (\u201cSEBI Master Circular\u201d) for above items is enclosed herewith as Annexure-I; The Press Release titled \u201cMankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies\u201d, being released by the Company, is also enclosed herewith as Annexure-II, which is self-explanatory. The meeting of Board of Directors of the Company commenced at 06:00 p.m. (IST) and concluded at 07:00 p.m. (IST). You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A\/a Annexure-I Disclosure as per Regulation 30 of the Listing Regulations read with SEBI Master Circular: S. No. Details of event that needs to be provided Details 1. Name of the target entity, details in brief such as size, turnover etc.; Name: Mankind Pharma (Netherlands) B.V. to acquire 70% stake in Armed Cell Therapeutics B.V. (\u201cACTx\u201d) Authorized share capital: EUR 50Mn Paid-up share capital: EUR 0.02Mn Turnover: Nil 2. Whether the acquisition would fall within related party transaction(s) and whether the promoter\/ promoter group\/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at \u201carm\u2019s length\u201d; Investment by Company into Mankind Netherlands, will be a related party transaction, being a wholly-owned subsidiary. Since, Mankind Netherlands is a wholly owned subsidiary of the Company, the aforesaid transaction between the Company and Mankind Netherlands is exempt under Regulation 23(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Except to the extent of stake held by the Company in Mankind Netherlands, the promoter\/promoter group\/group companies of the Company have no interest in Mankind Netherlands. The investment in ACTx by the Mankind Netherlands is not a related party transaction. 3. Industry to which the entity being acquired belongs; Pharmaceutical Industry 4. Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); The funds will be utilized by Mankind Netherlands to acquire a majority stake (i.e., 70%) in ACTx through an investment of EUR 48Mn, to be made in instalments. Said investment is part of the Company\u2019s long term strategy to build a global innovation-led pharmaceutical business. 5. Brief details of any governmental or regulatory approvals required for the acquisition; As may be required in compliance with laws of the host country 6. Indicative time period for completion of the acquisition; As per definitive agreement 7. Consideration - whether cash consideration or share swap or any other form and details of the same; Cash Consideration 8. Cost of acquisition and\/or the price at which the shares are acquired; The Company will make an additional investment of up to EUR 45Mn, in one or more tranches in Mankind Netherlands, aggregating to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn, which will be utilized to invest EUR 48Mn in installments in ACTx for acquiring 70% stake. 9. Percentage of shareholding \/ control acquired and \/ or number of shares acquired; The investment in Mankind Netherlands will not cause any change in the percentage of the Shareholding of the Company. It will continue to remain a wholly-owned subsidiary of the Company. 10. Brief background about the entity acquired in terms of products\/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); The Mankind Netherlands is an existing wholly owned subsidiary of the Company, incorporated in Netherlands on August 13, 2026, with the business objective of holding investments in R&D assets and undertaking business development activities focused on the treatment of niche therapies, either through joint ventures or by acquiring strategic interests as opportunities arise. The Mankind Netherlands was incorporated recently, hence turnover is Nil. ACTx, a Belgium-incorporated biotechnology company developing next-generation armed CAR-T (chimeric antigen receptor T cell) therapies for cancer and has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer. ACTx R&D activities are led by highly experienced teams located in US and EU. Press Release Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies Armed Cell Therapeutics is a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer. New Delhi, India, 15 th October, 2026: As a part of its long term strategy to build a global innovation- led pharmaceutical business, Mankind Pharma (BSE: 543904 | NSE: MANKIND) through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement under which Mankind Pharma will acquire a majority stake in Armed Cell Therapeutics B.V., a Belgium-incorporated biotechnology company developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies for cancer. Transaction Summary: \uf0b7 Mankind to invest EUR 48 million for 70% stake in Armed Cell Therapeutics \uf0b7 Armed Cell Therapeutics (ACTx) has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer \uf0b7 ACTx will pursue innovative means of CAR- T cell therapy including in vivo CAR-T cell generation \uf0b7 ACTx\u2019s R&D activities are led by highly experienced teams located in US and EU Armed Cell Therapeutics was founded by a team with experience in drug development, cell therapy and building companies. Its founders, include Paul Stoffels, MD, Chair of the Board, former Chief Executive Officer of Galapagos and former Chief Scientific Officer of Johnson & Johnson; John Mellors, MD, Chief Scientific Officer, Distinguished Professor of Medicine at the University of Pittsburgh and former SVP Discovery and Early Development at Galapagos; and Peter Verhaeghe, former Chair of argenx. CAR-T therapies have transformed the treatment of some blood cancers. Yet many patients relapse from lack of CAR-T cell persistence, CAR-T exhaustion or emergence of resistant cancer cells. Solid cancers are especially hard for CAR-T cells to penetrate and function in hostile tumor microenvironments. Armed CAR-T cells are engineered with additional payloads to strengthen and sustain their anti-tumor activity, with the goal of deeper and more durable responses. Targeting more than one cancer antigen is designed to make it harder for cancer cells to escape. Research and development activities by highly-experienced teams are located in the US and Europe. This partnership propels Mankind\u2019s vision of being an innovative, research-focused healthcare company and strengthens its ability to deliver advanced, innovation-led therapies globally, while remaining committed to quality, affordability and accessibility. Mr. Arjun Juneja, Chief Operating Officer, Mankind Pharma Ltd., shared, \u201cInnovation will be one of the defining growth engines for Mankind over the coming decades. This investment is the first step in building a global pipeline of breakthrough therapies. As the company scales its presence across complex and chronic therapy areas, Mankind, with this venture, is getting access to cutting-edge & differentiated scientific platforms, experienced leadership team and potential to generate multiple next-generation CAR-T candidates. Our long-term ambition is not only to participate in scientific Annexure-II Press Release innovation globally, but ultimately to make these transformative therapies more accessible to patients in India and around the world.\u201d Dr. Paul Stoffels, Chair of the Board, Armed Cell Therapeutics, shared, \u201cNext-generation CAR-T therapies can reach many more patients if we make them more powerful and durable. Armed Cell Therapeutics has the assets, the team and now the backing of Mankind to do exactly that. I am pleased to chair the Board and support the team.\u201d About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical companies in India, which focuses on the domestic market with its pan-India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro\/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women\u2019s health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists. For more information, visit www.mankindpharma.com About Armed Cell Therapeutics Armed Cell Therapeutics is a biotechnology company developing next-generation armed CAR-T therapies for cancer. Its lead programs focus on non-Hodgkin lymphoma, where relapse after current CAR-T therapy remains common, and small cell lung cancer, an aggressive tumor with few effective treatment options. The company is headquartered in Belgium, with operations in the Netherlands, research and pre-clinical operations in Pittsburgh, USA, and early development CAR-T cell therapy activities in Europe, Asia, and the United States. For more information, visit www.armedcelltx.com. About Dr. Paul Stoffels Paul Stoffels, MD, is Chair of the Board of Armed Cell Therapeutics. He is the former Chief Executive Officer of Galapagos and former Vice Chairman and Chief Scientific Officer of Johnson & Johnson. About Dr. John Mellors John W. Mellors, MD, is Chief Scientific Officer of Armed Cell Therapeutics and Distinguished Professor of Medicine at the University of Pittsburgh. He co-founded AboundBio and is the former SVP Discovery and Early Development at Galapagos. Press Release About Mr. Peter Verhaeghe Peter Verhaeghe is a corporate finance and life sciences lawyer and Managing Partner of VVGB Advocaten-Avocats. He is the former Chair of argenx (2008\u20132026) and an independent board member and chair of several European biotech companies and life sciences investment funds. Safe Harbour Statement The statements are as on date and may contain forward-looking statements like the words \u201cbelieve\u201d, \u201cexpects\u201d, \u201canticipate\u201d, \u201caim\u201d, \u201cwill likely result\u201d, \u201cwould\u201d, \u201cwill continue\u201d, \u201ccontemplate\u201d, \u201cintends\u201d, \u201cplans\u201d, \u201cestimates\u201d, \u201cseek to\u201d, \u201cfuture\u201d, \u201cobjective\u201d, \u201cprojects\u201d, \u201cgoal\u201d, \u201clikely\u201d, \u201cproject\u201d, \u201cshould\u201d, \u201cpotential\u201d, \u201cwill\u201d, \u201cmay\u201d, \u201ctargeting\u201d or other words of similar expressions\/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward- looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties, inter alia, relating to these statements include (i) cash flow projections; (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India\/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance. The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this press release or its contents or otherwise arising in connection therewith. Also, the Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent developments, information or events, or otherwise. For Queries Contact Mankind Pharma - Investor Relations Prakash Agarwal Email address: investor.relations@mankindpharma.com Contact Number: +91-11-46846700 Mankind Pharma - Corporate Communication Natasha Raj Email address: natasha.raj@mankindpharma.com Contact Number: 011-46846700 Ext: 3201 Adfactors PR - Investor Relations \/ Public Relations Smit Shah \/ Apoorva Sharma Email address: smit.shah@adfactorspr.com \/ apoorva.sharma@adfactorspr.com Contact Number: +91 9870789596 \/ +91 9999739452\"},{\"title\":\"Acquisition\",\"summary\":\"Acquisition\",\"source\":\"NSE\",\"published\":\"15-Oct-2026 19:28:15\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026192807_Outcomefinalsd.pdf\",\"disclosure_text\":\"October 15, 2026 BSE Limited P J Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Code: 543904 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Symbol: MANKIND Dear Sir\/ Madam, Sub.: Outcome of Board Meeting Ref.: Regulation 30 & 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cListing Regulations\u201d) The Board of Directors of Mankind Pharma Limited (\u201cCompany\u201d), at its meeting held today, i.e., October 15, 2026, has, inter alia, considered and approved: i. an additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V. (\u201cMankind Netherlands\u201d), a wholly owned subsidiary of the Company in Netherlands, in one or more tranches, thereby increasing the aggregate investment limit to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn; ii. the acquisition of a majority stake (i.e., 70%) in Armed Cell Therapeutics B.V. (\u201cACTx\u201d) through Mankind Netherlands. ACTx is a Belgium-incorporated biotechnology company engaged in the development of next-generation chimeric antigen receptor T-cell (\u201cCAR-T\u201d) therapies for cancer. ACTx has a pipeline of next-generation CAR-T assets, with its lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. The detailed disclosures as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO\/49\/14\/14(7)2025-CFD-POD2\/I\/3762\/2026 dated January 30, 2026 (\u201cSEBI Master Circular\u201d) for above items is enclosed herewith as Annexure-I; The Press Release titled \u201cMankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies\u201d, being released by the Company, is also enclosed herewith as Annexure-II, which is self-explanatory. The meeting of Board of Directors of the Company commenced at 06:00 p.m. (IST) and concluded at 07:00 p.m. (IST). You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A\/a Annexure-I Disclosure as per Regulation 30 of the Listing Regulations read with SEBI Master Circular: S. No. Details of event that needs to be provided Details 1. Name of the target entity, details in brief such as size, turnover etc.; Name: Mankind Pharma (Netherlands) B.V. to acquire 70% stake in Armed Cell Therapeutics B.V. (\u201cACTx\u201d) Authorized share capital: EUR 50Mn Paid-up share capital: EUR 0.02Mn Turnover: Nil 2. Whether the acquisition would fall within related party transaction(s) and whether the promoter\/ promoter group\/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at \u201carm\u2019s length\u201d; Investment by Company into Mankind Netherlands, will be a related party transaction, being a wholly-owned subsidiary. Since, Mankind Netherlands is a wholly owned subsidiary of the Company, the aforesaid transaction between the Company and Mankind Netherlands is exempt under Regulation 23(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Except to the extent of stake held by the Company in Mankind Netherlands, the promoter\/promoter group\/group companies of the Company have no interest in Mankind Netherlands. The investment in ACTx by the Mankind Netherlands is not a related party transaction. 3. Industry to which the entity being acquired belongs; Pharmaceutical Industry 4. Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); The funds will be utilized by Mankind Netherlands to acquire a majority stake (i.e., 70%) in ACTx through an investment of EUR 48Mn, to be made in instalments. Said investment is part of the Company\u2019s long term strategy to build a global innovation-led pharmaceutical business. 5. Brief details of any governmental or regulatory approvals required for the acquisition; As may be required in compliance with laws of the host country 6. Indicative time period for completion of the acquisition; As per definitive agreement 7. Consideration - whether cash consideration or share swap or any other form and details of the same; Cash Consideration 8. Cost of acquisition and\/or the price at which the shares are acquired; The Company will make an additional investment of up to EUR 45Mn, in one or more tranches in Mankind Netherlands, aggregating to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn, which will be utilized to invest EUR 48Mn in installments in ACTx for acquiring 70% stake. 9. Percentage of shareholding \/ control acquired and \/ or number of shares acquired; The investment in Mankind Netherlands will not cause any change in the percentage of the Shareholding of the Company. It will continue to remain a wholly-owned subsidiary of the Company. 10. Brief background about the entity acquired in terms of products\/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); The Mankind Netherlands is an existing wholly owned subsidiary of the Company, incorporated in Netherlands on August 13, 2026, with the business objective of holding investments in R&D assets and undertaking business development activities focused on the treatment of niche therapies, either through joint ventures or by acquiring strategic interests as opportunities arise. The Mankind Netherlands was incorporated recently, hence turnover is Nil. ACTx, a Belgium-incorporated biotechnology company developing next-generation armed CAR-T (chimeric antigen receptor T cell) therapies for cancer and has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer. ACTx R&D activities are led by highly experienced teams located in US and EU. Press Release Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies Armed Cell Therapeutics is a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer. New Delhi, India, 15 th October, 2026: As a part of its long term strategy to build a global innovation- led pharmaceutical business, Mankind Pharma (BSE: 543904 | NSE: MANKIND) through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement under which Mankind Pharma will acquire a majority stake in Armed Cell Therapeutics B.V., a Belgium-incorporated biotechnology company developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies for cancer. Transaction Summary: \uf0b7 Mankind to invest EUR 48 million for 70% stake in Armed Cell Therapeutics \uf0b7 Armed Cell Therapeutics (ACTx) has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer \uf0b7 ACTx will pursue innovative means of CAR- T cell therapy including in vivo CAR-T cell generation \uf0b7 ACTx\u2019s R&D activities are led by highly experienced teams located in US and EU Armed Cell Therapeutics was founded by a team with experience in drug development, cell therapy and building companies. Its founders, include Paul Stoffels, MD, Chair of the Board, former Chief Executive Officer of Galapagos and former Chief Scientific Officer of Johnson & Johnson; John Mellors, MD, Chief Scientific Officer, Distinguished Professor of Medicine at the University of Pittsburgh and former SVP Discovery and Early Development at Galapagos; and Peter Verhaeghe, former Chair of argenx. CAR-T therapies have transformed the treatment of some blood cancers. Yet many patients relapse from lack of CAR-T cell persistence, CAR-T exhaustion or emergence of resistant cancer cells. Solid cancers are especially hard for CAR-T cells to penetrate and function in hostile tumor microenvironments. Armed CAR-T cells are engineered with additional payloads to strengthen and sustain their anti-tumor activity, with the goal of deeper and more durable responses. Targeting more than one cancer antigen is designed to make it harder for cancer cells to escape. Research and development activities by highly-experienced teams are located in the US and Europe. This partnership propels Mankind\u2019s vision of being an innovative, research-focused healthcare company and strengthens its ability to deliver advanced, innovation-led therapies globally, while remaining committed to quality, affordability and accessibility. Mr. Arjun Juneja, Chief Operating Officer, Mankind Pharma Ltd., shared, \u201cInnovation will be one of the defining growth engines for Mankind over the coming decades. This investment is the first step in building a global pipeline of breakthrough therapies. As the company scales its presence across complex and chronic therapy areas, Mankind, with this venture, is getting access to cutting-edge & differentiated scientific platforms, experienced leadership team and potential to generate multiple next-generation CAR-T candidates. Our long-term ambition is not only to participate in scientific Annexure-II Press Release innovation globally, but ultimately to make these transformative therapies more accessible to patients in India and around the world.\u201d Dr. Paul Stoffels, Chair of the Board, Armed Cell Therapeutics, shared, \u201cNext-generation CAR-T therapies can reach many more patients if we make them more powerful and durable. Armed Cell Therapeutics has the assets, the team and now the backing of Mankind to do exactly that. I am pleased to chair the Board and support the team.\u201d About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical companies in India, which focuses on the domestic market with its pan-India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro\/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women\u2019s health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists. For more information, visit www.mankindpharma.com About Armed Cell Therapeutics Armed Cell Therapeutics is a biotechnology company developing next-generation armed CAR-T therapies for cancer. Its lead programs focus on non-Hodgkin lymphoma, where relapse after current CAR-T therapy remains common, and small cell lung cancer, an aggressive tumor with few effective treatment options. The company is headquartered in Belgium, with operations in the Netherlands, research and pre-clinical operations in Pittsburgh, USA, and early development CAR-T cell therapy activities in Europe, Asia, and the United States. For more information, visit www.armedcelltx.com. About Dr. Paul Stoffels Paul Stoffels, MD, is Chair of the Board of Armed Cell Therapeutics. He is the former Chief Executive Officer of Galapagos and former Vice Chairman and Chief Scientific Officer of Johnson & Johnson. About Dr. John Mellors John W. Mellors, MD, is Chief Scientific Officer of Armed Cell Therapeutics and Distinguished Professor of Medicine at the University of Pittsburgh. He co-founded AboundBio and is the former SVP Discovery and Early Development at Galapagos. Press Release About Mr. Peter Verhaeghe Peter Verhaeghe is a corporate finance and life sciences lawyer and Managing Partner of VVGB Advocaten-Avocats. He is the former Chair of argenx (2008\u20132026) and an independent board member and chair of several European biotech companies and life sciences investment funds. Safe Harbour Statement The statements are as on date and may contain forward-looking statements like the words \u201cbelieve\u201d, \u201cexpects\u201d, \u201canticipate\u201d, \u201caim\u201d, \u201cwill likely result\u201d, \u201cwould\u201d, \u201cwill continue\u201d, \u201ccontemplate\u201d, \u201cintends\u201d, \u201cplans\u201d, \u201cestimates\u201d, \u201cseek to\u201d, \u201cfuture\u201d, \u201cobjective\u201d, \u201cprojects\u201d, \u201cgoal\u201d, \u201clikely\u201d, \u201cproject\u201d, \u201cshould\u201d, \u201cpotential\u201d, \u201cwill\u201d, \u201cmay\u201d, \u201ctargeting\u201d or other words of similar expressions\/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward- looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties, inter alia, relating to these statements include (i) cash flow projections; (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India\/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance. The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this press release or its contents or otherwise arising in connection therewith. Also, the Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent developments, information or events, or otherwise. For Queries Contact Mankind Pharma - Investor Relations Prakash Agarwal Email address: investor.relations@mankindpharma.com Contact Number: +91-11-46846700 Mankind Pharma - Corporate Communication Natasha Raj Email address: natasha.raj@mankindpharma.com Contact Number: 011-46846700 Ext: 3201 Adfactors PR - Investor Relations \/ Public Relations Smit Shah \/ Apoorva Sharma Email address: smit.shah@adfactorspr.com \/ apoorva.sharma@adfactorspr.com Contact Number: +91 9870789596 \/ +91 9999739452\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Outcome of Board Meeting held on October 15, 2026.\",\"source\":\"NSE\",\"published\":\"15-Oct-2026 19:25:25\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026192506_Outcomefinalsd.pdf\",\"disclosure_text\":\"October 15, 2026 BSE Limited P J Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Code: 543904 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Symbol: MANKIND Dear Sir\/ Madam, Sub.: Outcome of Board Meeting Ref.: Regulation 30 & 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cListing Regulations\u201d) The Board of Directors of Mankind Pharma Limited (\u201cCompany\u201d), at its meeting held today, i.e., October 15, 2026, has, inter alia, considered and approved: i. an additional investment of up to EUR 45Mn in Mankind Pharma (Netherlands) B.V. (\u201cMankind Netherlands\u201d), a wholly owned subsidiary of the Company in Netherlands, in one or more tranches, thereby increasing the aggregate investment limit to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn; ii. the acquisition of a majority stake (i.e., 70%) in Armed Cell Therapeutics B.V. (\u201cACTx\u201d) through Mankind Netherlands. ACTx is a Belgium-incorporated biotechnology company engaged in the development of next-generation chimeric antigen receptor T-cell (\u201cCAR-T\u201d) therapies for cancer. ACTx has a pipeline of next-generation CAR-T assets, with its lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. The detailed disclosures as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO\/49\/14\/14(7)2025-CFD-POD2\/I\/3762\/2026 dated January 30, 2026 (\u201cSEBI Master Circular\u201d) for above items is enclosed herewith as Annexure-I; The Press Release titled \u201cMankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies\u201d, being released by the Company, is also enclosed herewith as Annexure-II, which is self-explanatory. The meeting of Board of Directors of the Company commenced at 06:00 p.m. (IST) and concluded at 07:00 p.m. (IST). You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A\/a Annexure-I Disclosure as per Regulation 30 of the Listing Regulations read with SEBI Master Circular: S. No. Details of event that needs to be provided Details 1. Name of the target entity, details in brief such as size, turnover etc.; Name: Mankind Pharma (Netherlands) B.V. to acquire 70% stake in Armed Cell Therapeutics B.V. (\u201cACTx\u201d) Authorized share capital: EUR 50Mn Paid-up share capital: EUR 0.02Mn Turnover: Nil 2. Whether the acquisition would fall within related party transaction(s) and whether the promoter\/ promoter group\/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at \u201carm\u2019s length\u201d; Investment by Company into Mankind Netherlands, will be a related party transaction, being a wholly-owned subsidiary. Since, Mankind Netherlands is a wholly owned subsidiary of the Company, the aforesaid transaction between the Company and Mankind Netherlands is exempt under Regulation 23(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Except to the extent of stake held by the Company in Mankind Netherlands, the promoter\/promoter group\/group companies of the Company have no interest in Mankind Netherlands. The investment in ACTx by the Mankind Netherlands is not a related party transaction. 3. Industry to which the entity being acquired belongs; Pharmaceutical Industry 4. Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); The funds will be utilized by Mankind Netherlands to acquire a majority stake (i.e., 70%) in ACTx through an investment of EUR 48Mn, to be made in instalments. Said investment is part of the Company\u2019s long term strategy to build a global innovation-led pharmaceutical business. 5. Brief details of any governmental or regulatory approvals required for the acquisition; As may be required in compliance with laws of the host country 6. Indicative time period for completion of the acquisition; As per definitive agreement 7. Consideration - whether cash consideration or share swap or any other form and details of the same; Cash Consideration 8. Cost of acquisition and\/or the price at which the shares are acquired; The Company will make an additional investment of up to EUR 45Mn, in one or more tranches in Mankind Netherlands, aggregating to EUR 50Mn, inclusive of the previously approved investment limit of EUR 5Mn, which will be utilized to invest EUR 48Mn in installments in ACTx for acquiring 70% stake. 9. Percentage of shareholding \/ control acquired and \/ or number of shares acquired; The investment in Mankind Netherlands will not cause any change in the percentage of the Shareholding of the Company. It will continue to remain a wholly-owned subsidiary of the Company. 10. Brief background about the entity acquired in terms of products\/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); The Mankind Netherlands is an existing wholly owned subsidiary of the Company, incorporated in Netherlands on August 13, 2026, with the business objective of holding investments in R&D assets and undertaking business development activities focused on the treatment of niche therapies, either through joint ventures or by acquiring strategic interests as opportunities arise. The Mankind Netherlands was incorporated recently, hence turnover is Nil. ACTx, a Belgium-incorporated biotechnology company developing next-generation armed CAR-T (chimeric antigen receptor T cell) therapies for cancer and has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer. ACTx R&D activities are led by highly experienced teams located in US and EU. Press Release Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies Armed Cell Therapeutics is a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer. New Delhi, India, 15 th October, 2026: As a part of its long term strategy to build a global innovation- led pharmaceutical business, Mankind Pharma (BSE: 543904 | NSE: MANKIND) through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement under which Mankind Pharma will acquire a majority stake in Armed Cell Therapeutics B.V., a Belgium-incorporated biotechnology company developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies for cancer. Transaction Summary: \uf0b7 Mankind to invest EUR 48 million for 70% stake in Armed Cell Therapeutics \uf0b7 Armed Cell Therapeutics (ACTx) has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer \uf0b7 ACTx will pursue innovative means of CAR- T cell therapy including in vivo CAR-T cell generation \uf0b7 ACTx\u2019s R&D activities are led by highly experienced teams located in US and EU Armed Cell Therapeutics was founded by a team with experience in drug development, cell therapy and building companies. Its founders, include Paul Stoffels, MD, Chair of the Board, former Chief Executive Officer of Galapagos and former Chief Scientific Officer of Johnson & Johnson; John Mellors, MD, Chief Scientific Officer, Distinguished Professor of Medicine at the University of Pittsburgh and former SVP Discovery and Early Development at Galapagos; and Peter Verhaeghe, former Chair of argenx. CAR-T therapies have transformed the treatment of some blood cancers. Yet many patients relapse from lack of CAR-T cell persistence, CAR-T exhaustion or emergence of resistant cancer cells. Solid cancers are especially hard for CAR-T cells to penetrate and function in hostile tumor microenvironments. Armed CAR-T cells are engineered with additional payloads to strengthen and sustain their anti-tumor activity, with the goal of deeper and more durable responses. Targeting more than one cancer antigen is designed to make it harder for cancer cells to escape. Research and development activities by highly-experienced teams are located in the US and Europe. This partnership propels Mankind\u2019s vision of being an innovative, research-focused healthcare company and strengthens its ability to deliver advanced, innovation-led therapies globally, while remaining committed to quality, affordability and accessibility. Mr. Arjun Juneja, Chief Operating Officer, Mankind Pharma Ltd., shared, \u201cInnovation will be one of the defining growth engines for Mankind over the coming decades. This investment is the first step in building a global pipeline of breakthrough therapies. As the company scales its presence across complex and chronic therapy areas, Mankind, with this venture, is getting access to cutting-edge & differentiated scientific platforms, experienced leadership team and potential to generate multiple next-generation CAR-T candidates. Our long-term ambition is not only to participate in scientific Annexure-II Press Release innovation globally, but ultimately to make these transformative therapies more accessible to patients in India and around the world.\u201d Dr. Paul Stoffels, Chair of the Board, Armed Cell Therapeutics, shared, \u201cNext-generation CAR-T therapies can reach many more patients if we make them more powerful and durable. Armed Cell Therapeutics has the assets, the team and now the backing of Mankind to do exactly that. I am pleased to chair the Board and support the team.\u201d About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical companies in India, which focuses on the domestic market with its pan-India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro\/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women\u2019s health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists. For more information, visit www.mankindpharma.com About Armed Cell Therapeutics Armed Cell Therapeutics is a biotechnology company developing next-generation armed CAR-T therapies for cancer. Its lead programs focus on non-Hodgkin lymphoma, where relapse after current CAR-T therapy remains common, and small cell lung cancer, an aggressive tumor with few effective treatment options. The company is headquartered in Belgium, with operations in the Netherlands, research and pre-clinical operations in Pittsburgh, USA, and early development CAR-T cell therapy activities in Europe, Asia, and the United States. For more information, visit www.armedcelltx.com. About Dr. Paul Stoffels Paul Stoffels, MD, is Chair of the Board of Armed Cell Therapeutics. He is the former Chief Executive Officer of Galapagos and former Vice Chairman and Chief Scientific Officer of Johnson & Johnson. About Dr. John Mellors John W. Mellors, MD, is Chief Scientific Officer of Armed Cell Therapeutics and Distinguished Professor of Medicine at the University of Pittsburgh. He co-founded AboundBio and is the former SVP Discovery and Early Development at Galapagos. Press Release About Mr. Peter Verhaeghe Peter Verhaeghe is a corporate finance and life sciences lawyer and Managing Partner of VVGB Advocaten-Avocats. He is the former Chair of argenx (2008\u20132026) and an independent board member and chair of several European biotech companies and life sciences investment funds. Safe Harbour Statement The statements are as on date and may contain forward-looking statements like the words \u201cbelieve\u201d, \u201cexpects\u201d, \u201canticipate\u201d, \u201caim\u201d, \u201cwill likely result\u201d, \u201cwould\u201d, \u201cwill continue\u201d, \u201ccontemplate\u201d, \u201cintends\u201d, \u201cplans\u201d, \u201cestimates\u201d, \u201cseek to\u201d, \u201cfuture\u201d, \u201cobjective\u201d, \u201cprojects\u201d, \u201cgoal\u201d, \u201clikely\u201d, \u201cproject\u201d, \u201cshould\u201d, \u201cpotential\u201d, \u201cwill\u201d, \u201cmay\u201d, \u201ctargeting\u201d or other words of similar expressions\/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward- looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties, inter alia, relating to these statements include (i) cash flow projections; (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India\/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance. The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this press release or its contents or otherwise arising in connection therewith. Also, the Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent developments, information or events, or otherwise. For Queries Contact Mankind Pharma - Investor Relations Prakash Agarwal Email address: investor.relations@mankindpharma.com Contact Number: +91-11-46846700 Mankind Pharma - Corporate Communication Natasha Raj Email address: natasha.raj@mankindpharma.com Contact Number: 011-46846700 Ext: 3201 Adfactors PR - Investor Relations \/ Public Relations Smit Shah \/ Apoorva Sharma Email address: smit.shah@adfactorspr.com \/ apoorva.sharma@adfactorspr.com Contact Number: +91 9870789596 \/ +91 9999739452\"}],\"shareholding_snapshot\":{\"promoter_pct\":72.63,\"public_pct\":27.37,\"fii_pct\":9.45,\"dii_pct\":15.39,\"mf_pct\":10.87,\"institutional_pct\":24.84,\"noninst_pct\":2.53,\"mf_scheme_count\":36,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"NIPPON LIFE INDIA TRUSTEE LTD-A\/C NIPPON INDIA NIF\",\"shares\":8547299,\"pct\":2.07},{\"name\":\"SBI ARBITRAGE OPPORTUNITIES FUND\",\"shares\":6426527,\"pct\":1.56}],\"period\":\"30-JUN-2026\",\"submission_date\":\"21-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1697698_21072026100612_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":72.66,\"previous_fii_pct\":10.24,\"previous_dii_pct\":14.46,\"previous_mf_pct\":10.36,\"previous_institutional_pct\":24.7,\"previous_mf_scheme_count\":31,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mankind Pharma stock in focus pre-market after approving a 70% stake acquisition in Armed Cell Therapeutics for CAR-T cancer therapies and receiving an ESG.<\/p>\n","protected":false},"author":1,"featured_media":6170,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Mankind Pharma in Focus After Acquiring Majority Stake in Armed Cell Therapeutics | 16 October 2026","_witty_meta_description":"Mankind Pharma stock in focus pre-market after approving a 70% stake acquisition in Armed Cell Therapeutics for CAR-T cancer therapies and receiving an ESG.","_witty_primary_phrase":"Mankind Pharma Armed Cell Therapeutics acquisition","_witty_reason_label":"Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[32],"class_list":["post-6171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-mankind"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/6171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=6171"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/6171\/revisions"}],"predecessor-version":[{"id":6172,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/6171\/revisions\/6172"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/6170"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=6171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=6171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=6171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}